NCT05183360View on ClinicalTrials.gov

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

PHASE1TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

August 12, 2022

Study Completion Date

August 8, 2024

Conditions
Healthy
Interventions
DRUG

BI 706321

BI 706321, tablet, oral use

DRUG

Placebo

Placebo, tablet, oral use

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY